Management of oligometastatic disease in soft tissue sarcomas
0Abstract
Oligometastatic soft tissue sarcoma represents an intermediate state between localized and disseminated disease. Combination A combination of surgery, radiotherapy and systemic treatment significantly improves prognosis, with a 5-year overall survival as high as 50%. Due to the high prevalence of lung metastases, most of the surgical evidence is centered around lung metastasectomy. The decision to perform surgical metastasectomy remains dependent on optimal patient selection. Adequate post-surgical lung function, absence of extrapulmonary metastases, control of the primary tumor, and feasibility of achieving negative margins are major criteria for patients to undergo successful surgery. Adequate margins, longer disease-free interval, unilateral, limited number
Keywords
INTRODUCTION
Soft tissue sarcomas (STS) are a heterogeneous group of neoplasms of mesenchymal origin composed of more than 50 different histologic subtypes[1]. STS represent 0.8% of all malignancies and result in 5,000 deaths each year in the US[2]. Most of these tumors display aggressive behavior, with high rates of metastatic disease[3]. Unlike other tumors, metastatic STS is often restricted to a single organ, with 70% of patients presenting metastasis limited to the lungs[4]. Despite the overall prevalence of lung metastasis, unusual patterns of metastatic spread characterize certain STS subtypes; extrapulmonary and brain metastasis are common in myxoid liposarcoma and alveolar soft part sarcoma, respectively[5,6]. Their prognosis depends on the presence of local recurrence and/or distant metastasis. Overall, these tumors have a 65% five-year survival rate, but this number drops to 16% in the case of metastatic sarcoma[2].
Oligometastatic disease, defined as less than five metastases in one organ or a limited number of organs, is considered an intermediate between localized and widespread metastatic disease[7]. This concept is increasingly being recognized as an opportunity to achieve long-term disease control through a combination of surgery to the metastatic site, systemic treatment, and radiation therapy (RT)[8]. Although guidelines for the management of oligometastatic disease for other malignancies are already in place, lower incidence of STS and high variability among histologic subtypes make it more difficult to implement large-scale trials and most evidence in this patient subset comes from single-institution studies, making recommendations inconsistent. The purpose of our study is to perform a comprehensive review of the literature to identify the most common approach to managing this condition that has been reported.
OVERVIEW OF TREATMENT OPTIONS
Management of oligometastatic disease in STS requires a multidisciplinary team and should consider the tumor histology and location, the number of metastases, and the interval of time preceding the development of metastasis. Treatment should aim at achieving local control, alleviation of symptoms, and improvement of prognosis[8,9].
Available treatment options include surgery to the metastatic site (metastasectomy), systemic treatment (cytotoxic, targeted therapy, and/or immunotherapy), and RT. Selection of treatment modality should always consider both the tumor characteristics (size, disease activity, treatment-resistance pattern) and the patient profile (health status, comorbidities). In most cases, a combination of surgery, systemic treatment, and/or RT is employed.
SURGERY
Surgery to the metastatic site has been described in the literature since the 1940s when Alexander et al. reported favorable outcomes after surgical resection of pulmonary metastases[10]. Although multiple retrospective cohort studies suggest positive outcomes for metastasectomy in oligometastatic disease, no randomized trials have ever been conducted, and the true benefit of surgery remains uncertain. In this setting, strict patient selection must be conducted to maximize the benefit of surgery.
Patient selection
Criteria for lung metastasectomy are highly variable due to different protocols among treating institutions. However, we consider an adaptation of the criteria utilized by Thomford et al. as a comprehensive approach to patient selection[11]. Candidates for lung metastasectomy must therefore fulfill the following criteria:
(I) Primary tumor eradicated, controlled, or amenable to control.
(II) Resection with adequate margins (R0) of the metastatic site is feasible.
(III) No evidence of extrapulmonary metastatic disease.
(IV) Patient can withstand the surgery, and post-surgery lung function is expected to be adequate.
Although most literature in oligometastatic STS refers to resection of lung metastasis, positive outcomes have also been reported with surgical management of liver metastasis[12]. We consider that these inclusion criteria can be adapted and applied to other metastatic sites, such as the liver.
Lung metastasis
Surgical approach in lung metastasectomy
The standard approach for unilateral pulmonary metastases is posterolateral thoracotomy[13]. Thoracotomy allows the surgeon to palpate the lung and locate additional nodules not found on preoperative imaging[9]. However, the main disadvantage is that exposure is limited to one hemithorax, and in the case of bilateral lung metastasis, the procedure must be performed in a staged fashion[13]. Video-Assisted Thoracic Surgery (VATS) is a minimally invasive approach that provides excellent lung visualization and decreased complication rates and length of stay compared to open surgery. The main disadvantage is, however, the loss of ability to palpate the lung and find new lesions not detected on preoperative imaging. Ultimately, the choice of surgical treatment depends on the surgeon’s experience.
Whether bilateral exploration is required in the presence of unilateral lung metastasis found on preoperative imaging remains controversial, due to the high prevalence of bilateral disease in STS and the limited sensitivity of chest CT for small lung nodules[14]. Roth et al. compared survival rates in patients who underwent resection of metastasis by sternotomy with an exploration of both lungs or with unilateral thoracotomy[15]. They found that although median sternotomy resulted in the detection of unsuspected metastasis, overall survival was not different. Further support against bilateral exploration is provided by Younes et al., who found no significant difference in overall survival in patients with recurrence in the contralateral lung and those with bilateral metastases on admission[16].
The location of the metastatic lesion is another important factor when choosing the most appropriate surgical approach to achieve sufficient surgical margins and thus diminish the risk of local recurrence. Peripheral nodules are considered accessible and adequate surgical margins can be obtained with wedge resection[17]. Central lesions are less accessible through VATS and segmentectomy is usually the recommended treatment[18].
Outcomes of lung metastasectomy
Suggestions of clinical benefit of lung metastasectomy come from observational studies. Reported five-year overall survival after lung metastasectomy ranges from 32% to 52%, which is superior to 5-year survival rates for metastatic STS as a whole[19-21]. The METASARC study, a French retrospective cohort with more than 2,000 patients with metastatic STS, reported a 44% five-year overall survival in patients receiving surgery to the metastatic site compared with 6.4% for radiotherapy alone[22]. Although the study did not perform a subgroup analysis for patients with only pulmonary metastasis, sixty-seven percent of patients included in the study had lung metastasis and 89% had only one metastatic site. Another issue with most available studies is the lack of a control group, limiting the generalizability of results. Nevala et al. retrospectively reported survival outcomes of 130 patients with STS and lung metastasis treated with either metastasectomy, chemotherapy, or supportive care[23]. Median overall survival after complete or incomplete metastasectomy, chemotherapy, or supportive care was 22, 18, 8 and 5 months, respectively. However, patients who did not receive surgical treatment because of exclusion criteria such as inadequate performance status or disseminated metastatic disease did not represent a proper control group.
Several prognostic factors have been reported in the literature for improved survival after lung metastasectomy [Table 1]. Here we present some of the most reported ones:
Factors associated with improved survival after lung metastasectomy
| Author (year) | Patient (n) | Surgical approach | Metastasectomy | Outcome measure(s) | Protective factors |
| Nevala et al., 2019[23] | 74 | Open thoracotomy (70%) VATS (30%) | Complete metastasectomy (55) incomplete metastasectomy (19) | 5-year DFS | (1) Single nodule removed in the last complete pulmonary resection+ (2) median DFI before last complete pulmonary resection < 1.3+ |
| Lee et al., 2016[21] | 29 | NA | Complete metastasectomy (100%) | 5-year OS | (1) Unilateral metastasis+ (2) early metastatic progression+ |
| Toussi et al., 2013[24] | 34 | Segmentectomy or wedge resection (70.6%) lobectomy (23.5%) and pneumonectomy (6%) | Complete metastasectomy (88%) incomplete metastasectomy (12%) | 3-year OS | (1) Unilateral metastasis+ (2) complete resection |
| Predina et al., 2011[20] | 48 | Open resection (73%) VATS (27%) | Complete metastasectomy (100%) | Median OS Median DFS | (1) Non-extrapulmonary metastasis+ |
| Sardenberg et al., 2010[25] | 77 | Open thoracotomy (97%) biopsy (3%) | Complete metastasectomy (79.2%) incomplete metastasectomy (20.8%) | Postoperative complication 30-day mortality rate 90-month OS | (1) Disease free interval (2) complete resection+ |
| Chudgar et al., 2017[26] | 539 | Open thoracotomy (71%) minimally invasive (29%) | Complete metastasectomy (91%) incomplete metastasectomy (9%) | Median OS Median DFS | (1) Low-grade primary tumor (2) synchronous interval to first metastasis (3) ≤ 1 pulmonary metastasis+ |
| Wigge et al., 2018[27] | 102 | Open thoracotomy (100%) | NA | Median OS | (1) Resection of primary tumor+ (2) progression-free interval < 12 months+ |
a. Adequate tumor resection (R0 margins)[23-25]
b. Disease-free interval (DFI) > 12 months[26], > 18 months[24], > 16 months[25]
c. Unilateral pulmonary metastasis[21,24]
d. Limited number (≤ 2) of pulmonary metastasis[20]
e. Small (< 2 cm) tumor size[20]
f. Metachronous metastases[26,27]
Chudgar et al. retrospectively reviewed 539 patients that underwent pulmonary metastasectomy for STS and found leiomyosarcoma histology, primary tumor size ≤ 10 cm, DFI > 12 months, solitary lung metastasis, and minimally invasive resection as factors associated with lower risk of death[26].
Although pulmonary metastasectomy is likely an effective treatment for improving patient prognosis, the risk of recurrence remains high even after successful R0 resection. Nevala et al. found an 82% rate of systemic recurrence after complete resection[23]. Other studies report similar rates of around 80%[21,26]. Although recurrence is a clear factor associated with a worse prognosis, localized lung recurrence in the absence of disseminated metastatic disease does not constitute a contraindication for secondary metastasectomy. Casson et al. analyzed 37 patients with secondary (recurrent) pulmonary metastasis after initial metastasectomy and reported a median survival of 28 months in patients with complete resection compared with 7 months for those with unresectable recurrent metastases[28].
Depending on the time of detection of metastases, they can be classified as synchronous or metachronous. Synchronous metastases are those detected at diagnosis, usually as a result of the imaging workup that follows the detection of an STS. Metachronous metastases, on the other side, occur after 3 months from the initial diagnosis, which typically means that the initial workup was negative for metastatic disease. Several studies have reported higher survival for patients with metachronous oligometastatic STS[26,27]. Chudgar et al. reported a median overall survival of 67 and 39 months for patients with metachronous and synchronous oligometastases, respectively[26]. They additionally performed a multivariate analysis which confirmed the worse prognosis associated with synchronous oligometastases (HR = 1.09, P = 0.037). The main limitation of this study was that the analysis combined patients with oligometastatic and disseminated diseases; however, patients with oligometastatic STS represented 64.9% (37/57) of the overall sample.
The case displayed in Figure 1 illustrates the surgical management of oligometastatic STS by the senior author of this article. The combination of wide excision for local control and lung metastasectomy yielded excellent results, as evidenced by the 4-year disease-free survival.
Figure 1. Fifty-six-year-old female with a diagnosis of synovial sarcoma in the right thigh underwent wide local excision 2 years prior to our consultation in an outside institution. She came to our clinic with right shoulder pain. Imaging studies showed an aggressive intramedullary lesion in the right proximal humerus with (A) T1-weighted hypointense, (B) STIR heterogeneous hyperintense, and (C) post-contrast heterogeneous enhancement. This lesion was biopsied and metastatic synovial sarcoma was diagnosed. Staging studies were done and a (D) solitary lung lesion was found suspicious for metastatic disease. The decision was made to start systemic therapy receiving two cycles, but (E) due to the growth of the lung lesion, the decision was made to proceed with (F) wide local excision of the right proximal humerus with reconstruction (reverse total shoulder replacement) and resection of the solitary lung lesion. The patient is 4 years out of surgery and is disease free.
Metastatic sites other than the lung
Outcomes of surgery to metastatic sites other than the lungs, especially the liver, have also been assessed in the literature[29-31]. Unlike lung metastasis, which in most cases manifests as solitary lesions, liver metastases are often present in patients with disseminated disease. Therefore, the curative role of surgery on metastatic liver lesions is under debate. Rehders et al. assessed the outcomes of 27 patients with STS with localized liver metastasis that underwent hepatic metastasectomy[32]. They reported a median survival of 44 months and a five-year survival of 49% after surgery[32]. In a similar study of 36 patients that underwent hepatic metastasectomy, Marudanayagam et al. found a median survival of 24 months and 5-year survival of 31.8%[12]. Potential limitations of these studies are the inclusion of gastrointestinal stromal tumors (GIST) and leiomyosarcoma, which in both cases represent more than 50% of all STS and are mostly localized in the abdomen and retroperitoneum. Other common STS, which most often involve the extremities, are underrepresented and robust conclusions cannot be drawn. These studies do, however, suggest a potential role for hepatic metastasectomy extending survival in a very select pool of patients with localized hepatic metastases. Although further research on this topic is needed, physicians should be aware that hepatic metastasis is usually seen as a manifestation of disseminated disease and localized hepatic metastases are an extremely infrequent event.
RADIATION THERAPY
During the last two decades, the median overall survival of patients with metastatic STS has improved by 50%. This can be partially attributed to the increased use of local treatments like RT, widespread use of systemic treatment, and improvement in supportive care[33,34]. RT has historically been used as palliative treatment due to the inaccurate concept of radioresistance in STS. Newer radiation treatment strategies such as Stereotactic Body Radiation Therapy (SBRT), a highly targeted hypo-fractionated ablative RT technique, have completely changed the paradigm and expanded the use of RT outside of palliative treatment[35,36]. SBRT works through a different mechanism than conventionally fractionated RT but shares the same dose escalation principle, especially in patients with oligometastatic disease where treatment has curative intent. Although STS are not as radiosensitive as other solid malignancies, several studies have demonstrated that high rates of local control can be achieved through RT[35,37-40].
SBRT offers several advantages over surgery or radiofrequency for local control as it is non-invasive, can deliver high biological doses of radiation with minimum damage to the surrounding normal tissue, does not cause significant patient discomfort, and has a lower 30- and 90-day postoperative mortality than surgery. Disadvantages of SBRT include self-resolving acute grade 1 toxicity and grade 2 toxicities requiring medical management in 10% of cases[35]. In addition, the number of metastases treated through RT is often limited by the radiation tolerance of surrounding tissues[9,38]. Literature on SBRT-related toxicity is conflicting, with multiple studies on STS lung metastases reporting minimal toxicity after treatment[34,35,37-39,41,42]. Loi et al. reported good tolerance to SBRT independent of the irradiated site in 16 patients after a median follow-up of 36 months[35]. Only 10% of patients presented with grade 2 toxicity that required medical and no chronic toxicities were observed[33]. However, additional studies on both primary lung tumors and lung metastasis treated with SBRT reported higher rates of toxicity that varied according to lesion location[43,44]. Chest wall toxicity, which includes chest wall pain and rib fractures, is a known adverse effect of SBRT on peripheric lung lesions with a reported incidence between 8%-46%[43]. For centrally-located lesions, adverse events included respiratory, gastrointestinal and cardiac events[44]. A study by Modh et al. reported an 8% incidence of ≥ grade 3 adverse events, including two deaths, in 125 patients with central lesions treated with 45 Gy of SBRT[44]. Another important limitation of RT treatment for lung metastases is the radiation tolerance of surrounding tissues[9,36].
Multiple retrospective studies have shown encouraging results in patients with oligometastatic disease regarding local control and survival rates[34-41,45]. SBRT can achieve successful local control over multiple tumor locations, sizes, and tumor subtypes, but is less effective for sites of tumor recurrence or near a site of prior SBRT or metastasectomy[37]. In this section, we seek to review the outcomes of RT in STS oligometastatic disease in the most common metastatic sites.
Radiation therapy in lung metastases
Metastasectomy has been the local treatment of choice for lung metastasis in the absence of disseminated extrapulmonary disease. However, it is associated with significant morbidity and mortality, and relapse occurs in around 80% of patients after metastasectomy[46,47]. In this setting, SBRT can provide an additional method of achieving effective local control of the metastatic site[41].
Retrospective studies assessing the outcomes in patients with pulmonary metastases from STS have reported 2-year local control rates between 86 and 88% and a 2-year overall survival ranging from 43% to 96% in patients receiving SBRT[37-39,41]. In all studies, mean overall survival remained below 30 months[37,39,41,48]. Similar radiation doses (50-54 Gy) and fractionation schemes (3-5 fractions) were employed by the studies, indicating consistency in treatment strategies. However, one retrospective study of 16 patients by Loi et al. did report a four-year overall survival of 54% and a median overall survival of 5.75 years[35]. The superior outcomes of this study reflect a possible selection bias as only patients with oligometastatic disease and controlled primary tumors were included. In comparison, most other studies included all patients with lung metastasis irrespective of control of the primary tumor or extrapulmonary metastasis. The true effect of SBRT remains unknown because most of the patients undergo surgery before RT and those that do not usually have more advanced disease or comorbidities that worsen prognosis, resulting in selection bias.
In patients undergoing RT, it is important to identify factors associated with poor treatment response and worse prognosis. Loi et al. found that a disease-free interval < 24 months from initial diagnosis to first metastasis was the only predictor of reduced local control, disease-free survival, and overall survival[35]. This might be explained by an inverse relationship between time from initial diagnosis and the duration of the scattering phase of malignant cells from the primary tumor[45,49]. No additional data on prognostic factors for success or failure of SBRT in oligometastatic STS is available, if not resulting from surgical studies.
Radiation therapy in spine metastases
Spine metastases in STS are rare, and published studies about therapeutic approaches towards spinal cord or root involvement are limited to case reports or small case series[40,45,50,51]. Surgical management offers the best option for local control, but its feasibility is limited mainly because of the anatomical location of the lesion and limited marginal or wide resections[40,50]. RT also presents limitations given the radiosensitivity of the spine. Oncologic emergencies like spinal cord compression are difficult to manage because patients are usually not good surgical candidates, and chemotherapy is usually not useful because of chemoresistance or previous exposure. RT can only be used with low doses that are far below the required doses for eradication and are usually indicated only as palliative management[50].
SBRT, however, allows larger effective doses of radiation to be delivered to spinal tumors without radiation injury. Thames et al. described that sarcomas may have a lower alpha/beta ratio, making hypofractionated RT probably a more effective option[52]. Chang et al. report a series with a median survival of 21 months and a local progression-free survival of 20 months[40]. Less favorable results were reported by Merismky et al., with improvement in pain and performance in 14 out of 23 cases and a lower median survival of 5 months[50]. Based on these results, hypofractionation radiation delivery obtains better local control and survival in metastatic spinal sarcomas than conventional RT[40].
Radiation therapy in brain metastases
Brain metastases in STS are uncommon, frequently preceded by lung metastasis, and their incidence is not precisely known[6,53]. There is no consensus regarding the management of brain metastases and a multidisciplinary approach is required. Gonzalez et al. conducted a SEER population-based cohort study and reported that surgical resection with or without adjuvant RT represented the most frequent treatment with no statistically significant difference in the overall use of RT[6]. Patients with all known lesions surgically removed tend to live longer[54].
SBRT is usually applied in cases of sarcoma brain metastasis alone or in combination with whole-brain RT. Increasing the amount of radiation in a single fraction appears to increase efficacy[53]. When SBRT is combined with whole-brain radiation (WBRT), the local control is improved because of the cumulative dosage delivered. The 1-year survival rate was not significant, with 38.5% in the WBRT + SBRT and 28.4%
INTERVENTIONAL RADIOLOGY
Image-guided interventional therapies are increasingly becoming more popular in metastatic STS. Procedures like percutaneous thermal ablation (PTA) or arterial embolization may be used as alternatives or complements to surgery or RT in patients with oligometastatic disease[9]. Ablation aims to achieve the same goal as surgical resection, but instead of removing the tumor, it destroys the tumor cells in situ. Despite destroying most of the tumor, remnants of antigens remain. This feature of ablation can stimulate a systemic antitumor immune response that surgical resection cannot. While ablation therapies alone can elicit immune responses, they are often not potent enough to induce a strong antitumor response. Combining immunomodulators with traditional ablative techniques can augment the induced immune response, leading to systemic antitumor activity. Promising evidence suggests that this synergistic enhancement of the immune response can be effective[56].
PTA can be categorized as burning (radiofrequency, microwave, highly-intensity focused ultrasound) or freezing (cryoablation). PTA is a minimally invasive procedure that can be performed in an outpatient setting, has minimal complications, decreased morbidity, and reduced recovery time compared to surgery. This treatment strategy is usually reserved for patients who are not surgical candidates, refuse elective surgery or have failed other treatments.
While percutaneous image-guided cryoablation has limited evidence for managing STS, studies suggest it could benefit patients with recurrent or unresectable lesions for both curative and palliative treatment. The technique offers advantages such as intraprocedural monitoring for accuracy and the ability to target irregularly shaped lesions with multiple probes. However, it is important to maintain an adequate distance from the skin and neurovascular structures to avoid necrosis[57].
A case treated with cryoablation by one of the authors is displayed in Figure 2.
Figure 2. Seventy-year-old patient with a diagnosis of extraskeletal osteosarcoma of the right thigh. She underwent preoperative radiation and wide local excision. One year later, she developed a soft tissue mass within the subcutaneous gluteal area. This was a biopsy-proven metastatic lesion. Staging studies did not show additional metastatic disease. The decision was made to perform local control with cryoablation. The mass can be seen on (A) T1 and (B) post-contrast imaging prior to cryoablation. Cryoablation was successful (C), and the post-cryoablation results can be seen on (D) T1 and (E) post-contrast imaging. At six months post-procedure, the patient is disease free.
Radiofrequency ablation (RFA) is the most common ablation technique in metastatic STS, with reported one- and three-year overall survival of 92.2% and 65.2%[58]. A French multicenter trial in 213 patients with oligometastatic STS reported that local treatment, which included RFA in 16% of cases, resulted in a median overall survival of 45.3 months compared to 18.6 months in those without local treatment[59]. Although the study suggested improved outcomes with RFA, significant overlap with surgery for local control was present and did not allow for individually assessing the efficacy of RFA.
Arterial embolization is another interventional radiology treatment aimed at suppressing blood supply to the metastatic site, resulting in ischemia and tumor necrosis. Image-guided arterial embolization is primarily indicated for patients with unresectable sarcoma and isolated hepatic metastases or minimal extrahepatic disease. Rajan et al. reported a 40% three-year overall survival and a median survival of 13 months in patients with sarcomas metastatic to the liver after chemoembolization with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol particles[60].
Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) has shown promise in improving bone pain and quality of life in patients with disseminated disease and focal metastatic bone pain that is unresponsive to palliative radiotherapy[61,62]. While data regarding the management of bone metastasis in STS is limited, several studies suggest that MR-HIFU could be a valuable tool for the palliative management of STS oligometastatic disease[61-63].
SYSTEMIC TREATMENT AND TARGETED THERAPY
The efficacy of chemotherapy in oligometastatic STS remains controversial due to conflicting evidence. The high heterogeneity between STS subtypes and the low prevalence of this malignancy has limited the development of effective systemic therapies, and no major breakthroughs have occurred in the last 20 years. Furthermore, most treatment guidelines are biased in favor of the most common STS such as liposarcoma, leiomyosarcoma, and undifferentiated pleomorphic sarcoma[64].
In the 1970s, the treatment of sarcomas was based on the use of vincristine, actinomycin-D, and cyclophosphamide (VAC)[65]. Although the VAC regimen showed clinical responses as high as 23.5%, most studies that evaluated this clinical response were conducted in pediatric rhabdomyosarcoma. Still, in other types of STS, the clinical response was even lower[65]. Doxorubicin, an antitumor antibiotic, was introduced at the same time, with studies showing a response rate of 10%-25% among all STS types[66]. However, the response rate can be altered depending on the dose: 0% at 25 mg/m2, 11% at 50 mg/m2, 20% at 60 mg/m2, and 37% at 75 mg/m2[67]. Modern studies target 75 mg/m2 of doxorubicin as an adequate dose[68], with higher doses being barely used due to the risk of toxicity and marginal benefits. Currently, doxorubicin is considered the most effective agent and is consistently used in the treatment of STS.
A study made by the European Cooperative Oncology Group (ECOG) compared doxorubicin to doxorubicin plus ifosfamide[69]. The combination regimen showed a response rate of 34%, compared to 20% in the group receiving doxorubicin (P = 0.03). However, the use of combination chemotherapy had considerably more myelosuppression and no improvement in overall survival[69]. It is important to note that this study was done prior to the availability of hematopoietic growth factors. Both treatments were again compared in a phase 3 randomized controlled trial (RCT). Combination therapy, doxorubicin (75 mg/m2) plus ifosfamide (10 g/m2), was compared with single-agent doxorubicin (75 mg/m2); both groups received growth factor support[70]. The trial reported no significant difference (P = 0.075) in overall median survival between the combination group (14.4 months) and the doxorubicin group (12.8 months). However, statistically superior median progression-free survival and overall response were found in the combination group[70]. Due to the lack of a clear survival benefit, the authors concluded that the addition of ifosfamide should be kept for patients in whom tumor shrinkage is specifically desired[71].
Systemic treatment by histology
In addition to providing an overview of systemic treatment in oligometastatic disease, we consider it important to review some of the histopathologic STS with clearly defined chemotherapy regimens.
(a) Liposarcoma
Anthracycline-based chemotherapy is used as a first-line treatment for advanced-stage or metastatic liposarcoma. Subgroup analysis of a phase 3 RCT in advanced STS showed that liposarcoma had a stronger tumor response to chemotherapy than other subtypes[72]. Additional studies have reinforced the efficacy of doxorubicin-based therapy, especially in patients with myxoid liposarcoma and round cell liposarcoma[71].
(b) Leiomyosarcoma
Doxorubicin is the drug of choice in non-uterine leiomyosarcoma. The use of ifosfamide is usually held as a second-line treatment because of its worse toxic profile. Other second-line regimens include gemcitabine + docetaxel, and trabectedin.
In uterine cases, gemcitabine plus docetaxel has shown to be the most helpful treatment and should be used as the first line. Second-line options include doxorubicin, trabectedin, or temozolomide[73].
(c) Synovial sarcoma
Synovial sarcoma is acknowledged as one of the most chemo-sensitive subtypes of STS and is particularly sensitive to alkylating agents. Combination of doxorubicin plus ifosfamide is highly recommended for these cases. Furthermore, some patients with synovial sarcoma appear to benefit from trabectedin[74].
(d) Epithelioid sarcoma
Although rare, this type of cancer is highly aggressive. A recent international phase 2 study demonstrated the potential of Tazemetostat in treating individuals with advanced epithelioid sarcoma that had a deletion of INI1/SMARCB1[75]. Moreover, Tazemostat showed a good safety profile, with the most common side effects being fatigue, nausea, and decreased appetite.
Targeted therapy
Targeted therapies have revolutionized the current treatment of specific STS histologies, offering great treatment response with a much better adverse events profile than standard chemotherapy. Since the 2000s, multitarget tyrosine kinase inhibitors have become available and serve as a powerful complement to cytotoxic therapy. Pazopanib, a VEGF receptor inhibitor, has been approved for the treatment of non-adipocytic STS[71]. In a phase 3 RCT, pazopanib showed significant improvement in progression-free survival in non-adipocytic STS; however, overall survival was not different between treatments[76]. Other target therapies are useful in certain STS histologic subtypes. In patients with dermatofibrosarcoma protuberans (t17;22), imatinib has shown clinical benefit[77]. Other potential effective targeted therapies include crizotinib in inflammatory myofibroblastic tumors[78] and cediranib and sunitinib in alveolar soft part sarcoma[79]. One of the greatest success stories of targeted therapy in STS is GIST, where imatinib and sunitinib have shown high rates of treatment response and disease remission[80]. In the setting of metastatic disease by GIST, approximately one-third of patients can achieve disease control for 5 years after treatment with tyrosine-kinase inhibitors[81]. Another promising targeted therapy is larotrectinib, which inhibits TrkA, TrkB, and TrkC. Recent phase 1 and 2 clinical trials investigating the efficacy of larotrectinib in fusion-positive cancers found that 55% of patients responded to treatment, and those who received treatment remained free of progression after one year with no significant adverse events reported[82]. Additionally, a recent case report reported the successful use of larotrectinib in treating an NTRK fusion cervical sarcoma, resulting in no evidence of disease at imaging after 15 months of treatment[83] Larotrectinib has also shown effectiveness in treating NTRK-rearranged spindle cell neoplasms[84]. Although an in-depth review of currently available targeted therapy drugs goes beyond the scope of this article, we consider that a summary of available drugs and the molecular pathways involved might be helpful to the reader [Figure 3].
Figure 3. Current targeted therapies for soft tissue sarcomas and their associated pathways. Displayed with permission from
CONCLUSIONS
Oligometastatic STS is an increasingly recognized tumor presentation with an opportunity to achieve long-term tumor control. A multidisciplinary approach combining surgery, radiation therapy, and systemic treatment is usually employed. Lung metastasectomy through either thoracotomy or Video-Assisted Thoracic Surgery (VATS) yields excellent results in patients with oligometastatic disease. Successful results in sites other than the lungs, such as the liver, have also been described. Radiation therapy is an effective (neo)-adjuvant treatment and has a role in both local control and palliation. However, its efficacy in the absence of surgery has not yet been proven. Systemic treatment, widely employed as adjuvant therapy in metastatic STS, has limited efficacy due to high tumor heterogeneity.
In the setting of a rare family of tumors such as STS, future studies should focus on improving the diagnostic and treatment guidelines for oligometastatic STS. Oligometastatic disease in STS still lacks clear boundaries, and treatment is extremely heterogeneous. Therefore, studies should now focus on approaching oligometastatic STS with a standard treatment that can later be implemented on a wider scale. Although the development of new drugs for STS remains elusive, recent successes such as the Alliance A091401 have shown that trials can be completed in a time-efficient manner. Open-label trials such as the Alliance study can therefore streamline the assessment of the efficacy of newer drugs in a rare disease such as STS.
DECLARATIONS
Authors’ contributionsMade substantial contributions to the conception and design of the study and was involved in manuscript writing: Gonzalez MR, Inchaustegui ML, Ruiz-Arellanos K, de Souza FF, Subhawong TK, Pretell-Mazzini J
Availability of data and materialsNot applicable.
Financial support and sponsorshipNone.
Conflicts of interestAll authors declared that there are no conflicts of interest.
Ethical approval and consent to participateNot applicable.
Consent for publicationNot applicable.
Copyright© The Author(s) 2023.
REFERENCES
1. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica 2021;113:70-84.
3. Kawamoto T, Hara H, Morishita M, et al. Prognostic influence of the treatment approach for pulmonary metastasis in patients with soft tissue sarcoma. Clin Exp Metastasis 2020;37:509-17.
4. Gadd MA, Casper ES, Woodruff JM, McCormack PM, Brennan MF. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg 1993;218:705-12.
5. Smith HG, Memos N, Thomas JM, Smith MJ, Strauss DC, Hayes AJ. Patterns of disease relapse in primary extremity soft-tissue sarcoma. Br J Surg 2016;103:1487-96.
6. Gonzalez MR, Bryce-Alberti M, Leon-Abarca JA, Pretell-Mazzini J. Brain metastases in patients with soft-tissue sarcomas: management and survival-a seer population-based cohort study. J Am Acad Orthop Surg Glob Res Rev 2021;5:1-10.
8. Walls GM, Zaidi SH, Fotiadis N, et al. Treatments and outcomes in oligometastatic soft tissue soft sarcoma - a single centre retrospective analysis. Anticancer Res 2021;41:5089-96.
9. Grilley-Olson JE, Webber NP, Demos DS, Christensen JD, Kirsch DG. Multidisciplinary management of oligometastatic soft tissue sarcoma. Am Soc Clin Oncol Educ Book 2018;38:939-48.
10. Alexander J, Haight C. Pulmonary resection for solitary metastatic sarcomas and carcinomas; 1946. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20282935 [Last accessed on 12 Apr 2023].
11. Thomford NR, Woolner LB, Clagett OT. The surgical treatment of metastatic tumors in the lungs. J Thorac Cardiovasc Surg 1965;49:357-63.
12. Marudanayagam R, Sandhu B, Perera MT, et al. Liver resection for metastatic soft tissue sarcoma: an analysis of prognostic factors. Eur J Surg Oncol 2011;37:87-92.
13. Quiros RM, Scott WJ. Surgical treatment of metastatic disease to the lung. Semin Oncol 2008;35:134-46.
14. Margaritora S, Porziella V, D ‘Andrilli A, et al. Pulmonary metastases: can accurate radiological evaluation avoid thoracotomic approach? Eur J Cardiothorac Surg 2002;21:1111-4.
15. Roth JA, Pass HI, Wesley MN, White D, Putnam JB, Seipp C. Comparison of median sternotomy and thoracotomy for resection of pulmonary metastases in patients with adult soft-tissue sarcomas. Ann Thorac Surg 1986;42:134-8.
16. Younes RN, Gross JL, Deheinzelin D. Surgical resection of unilateral lung metastases: is bilateral thoracotomy necessary? World J Surg 2002;26:1112-6.
17. Mangiameli G, Cioffi U, Alloisio M, Testori A. Lung Metastases: current surgical indications and new perspectives. Front Surg 2022;9:884915.
18. Shiono S, Matsutani N, Hashimoto H, et al. Prospective study of recurrence at the surgical margin after wedge resection of pulmonary metastases. Gen Thorac Cardiovasc Surg 2021;69:950-9.
19. Schur S, Hoetzenecker K, Lamm W, et al. Pulmonary metastasectomy for soft tissue sarcoma-report from a dual institution experience at the Medical University of Vienna. Eur J Cancer 2014;50:2289-97.
20. Predina JD, Puc MM, Bergey MR, et al. Improved survival after pulmonary metastasectomy for soft tissue sarcoma. J Thorac Oncol 2011;6:913-9.
21. Lee K, Kang MC, Lee HW, et al. Pulmonary metastasectomy in adult patients with synovial sarcoma: a single-center experience. Korean J Thorac Cardiovasc Surg 2016;49:451-5.
22. Savina M, Le Cesne A, Blay JY, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med 2017;15:78.
23. Nevala R, Jäämaa S, Tukiainen E, et al. Long-term results of surgical resection of lung metastases from soft tissue sarcoma: a single center experience. J Surg Oncol 2019;120:168-75.
24. Toussi MS, Bagheri R, Dayani M, Anvari K, Sheibani S. Pulmonary metastasectomy and repeat metastasectomy for soft-tissue sarcoma. Asian Cardiovasc Thorac Ann 2013;21:437-42.
25. Sardenberg RA, Figueiredo LP, Haddad FJ, Gross JL, Younes RN. Pulmonary metastasectomy from soft tissue sarcomas. Clinics 2010;65:871-6.
26. Chudgar NP, Brennan MF, Munhoz RR, et al. Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. J Thorac Cardiovasc Surg 2017;154:319-330.e1.
27. Wigge S, Heißner K, Steger V, et al. Impact of surgery in patients with metastatic soft tissue sarcoma: a monocentric retrospective analysis. J Surg Oncol 2018;118:167-76.
28. Casson AG, Putnam JB, Natarajan G, et al. Efficacy of pulmonary metastasectomy for recurrent soft tissue sarcoma. J Surg Oncol 1991;47:1-4.
29. Shima Y, Horimi T, Ishikawa T, et al. Aggressive surgery for liver metastases from gastrointestinal stromal tumors. J Hepatobiliary Pancreat Surg 2003;10:77-80.
30. Lang H, Nussbaum KT, Kaudel P, Frühauf N, Flemming P, Raab R. Hepatic metastases from leiomyosarcoma: a single-center experience with 34 liver resections during a 15-year period. Ann Surg 2000;231:500-5.
31. DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001;234:540-7; discussion 547.
32. Rehders A, Peiper M, Stoecklein NH, et al. Hepatic metastasectomy for soft-tissue sarcomas: is it justified? World J Surg 2009;33:111-7.
33. Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011;117:1049-54.
34. Soyfer V, Corn BW, Shtraus N, et al. Single-institution experience of SBRT for lung metastases in sarcoma patients. Am J Clin Oncol 2017;40:83-5.
35. Loi M, Duijm M, Baker S, et al. Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma. Radiol Med 2018;123:871-8.
36. Fuller BG. The role of radiation therapy in the treatment of bone and soft-tissue sarcomas. In: Musculoskeletal cancer surgery. Kluwer Academic Publishers; 1976. pp. 85-133. Available from: https://tumorsurgery.org/Portals/0/PDF/Textbooks/ch5.pdf [Last accessed on 15 Apr 2023].
37. Baumann BC, Nagda SN, Kolker JD, et al. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: a potential alternative to resection. J Surg Oncol 2016;114:65-9.
38. Mehta N, Selch M, Wang PC, et al. Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma. Sarcoma 2013;2013:360214.
39. Navarria P, Ascolese AM, Cozzi L, et al. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer 2015;51:668-74.
40. Chang UK, Cho WI, Lee DH, et al. Stereotactic radiosurgery for primary and metastatic sarcomas involving the spine. J Neurooncol 2012;107:551-7.
41. Dhakal S, Corbin KS, Milano MT, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys 2012;82:940-5.
42. Frakulli R, Salvi F, Balestrini D, et al. Stereotactic radiotherapy in the treatment of lung metastases from bone and soft-tissue sarcomas. Anticancer Res 2015;35:5581-6.
43. Thompson M, Rosenzweig KE. The evolving toxicity profile of SBRT for lung cancer. Transl Lung Cancer Res 2019;8:48-57.
44. Modh A, Rimner A, Williams E, et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2014;90:1168-76.
45. Folkert MR, Bilsky MH, Tom AK, et al. Outcomes and toxicity for hypofractionated and single-fraction image-guided stereotactic radiosurgery for sarcomas metastasizing to the spine. Int J Radiat Oncol Biol Phys 2014;88:1085-91.
46. Weiser MR, Downey RJ, Leung DH, Brennan MF. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg 2000;191:184-90; discussion 190.
47. Blackmon SH, Shah N, Roth JA, et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg 2009;88:877-84; discussion 884.
48. Mohammed S, Basu A, Jilani A, et al. Primary squamous cell carcinoma of the toe masquerading as osteomyelitis: A case report aasim mohammed. Anticancer Res 2015;35:6704. Available from: https://ar.iiarjournals.org/content/anticanres/35/12/6695.full.pdf [Last accessed on 12 Apr 2023]
49. Withers HR, Lee SP. Modeling growth kinetics and statistical distribution of oligometastases. Semin Radiat Oncol 2006;16:111-9.
50. Merimsky O, Kollender Y, Bokstein F, et al. Radiotherapy for spinal cord compression in patients with soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2004;58:1468-73.
51. Levine AM, Coleman C, Horasek S. Stereotactic radiosurgery for the treatment of primary sarcomas and sarcoma metastases of the spine. Neurosurgery 2009;64:A54-9.
52. Thames HD, Suit HD. Tumor radioresponsiveness versus fractionation sensitivity. Int J Radiat Oncol Biol Phys 1986;12:687-91.
53. Qasem S. Biology and treatment of metastasis of sarcoma to the brain. Front Biosci 2016;8:233-44.
54. Salvati M, D' Elia A, Frati A, Santoro A. Sarcoma metastatic to the brain: a series of 35 cases and considerations from 27 years of experience. J Neurooncol 2010;98:373-7.
55. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-91.
56. Slovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS. Immuno-thermal ablations - boosting the anticancer immune response. J Immunother Cancer 2017;5:78.
57. Vanni S, De Vita A, Gurrieri L, et al. Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives. Ther Adv Med Oncol 2022;14:17588359221093973.
58. Palussière J, Italiano A, Descat E, et al. Sarcoma lung metastases treated with percutaneous radiofrequency ablation: results from 29 patients. Ann Surg Oncol 2011;18:3771-7.
59. Falk AT, Moureau-Zabotto L, Ouali M, et al. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. Clin Oncol 2015;27:48-55.
60. Rajan DK, Soulen MC, Clark TW, et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 2001;12:187-93.
61. Harding D, Giles SL, Brown MRD, et al. Evaluation of quality of life outcomes following palliative treatment of bone metastases with magnetic resonance-guided high intensity focused ultrasound: an international multicentre study. Clin Oncol 2018;30:233-42.
62. Bongiovanni A, Foca F, Oboldi D, et al. 3-T magnetic resonance-guided high-intensity focused ultrasound (3-T-MR-HIFU) for the treatment of pain from bone metastases of solid tumors. Support Care Cancer 2022;30:5737-45.
63. Vincenzi B, Frezza AM, Schiavon G, et al. Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. Clin Sarcoma Res 2013;3:6.
64. Meyer M, Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Curr Treat Options Oncol 2019;20:6.
65. Jacobs EM. Combination chemotherapy of metastatic testicular germinal cell tumors and soft part sarcomas. Cancer 1970;25:324-32.
66. Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol 2014;11:187-202.
67. O ‘bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977;39:1940-8.
69. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75.
70. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014;15:415-23.
71. Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin 2020;70:200-29.
72. Young RJ, Litière S, Lia M, et al. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. Acta Oncol 2017;56:1013-20.
73. Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol 2010;21 Suppl 7:vii270-6.
74. Carroll C, Patel N, Gunsoy NB, Stirnadel-Farrant HA, Pokras S. Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond). Future Oncol 2022;18:3651-65.
75. Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol 2020;21:1423-32.
76. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.
77. Henry OS, Platoff R, Cerniglia KS, et al. Tyrosine kinase inhibitors versus radiation therapy in unresectable dermatofibrosarcoma protuberans (DFSP): a narrative systematic review. Am J Surg 2023;225:268-74.
78. Kasper B, Ströbel P, Hohenberger P. Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist 2011;16:682-93.
79. Paoluzzi L, Maki RG. Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: a review. JAMA Oncol 2019;5:254-60.
80. Khan J, Ullah A, Waheed A, et al. Gastrointestinal stromal tumors (GIST): a population-based study using the SEER database, including management and recent advances in targeted therapy. Cancers 2022;14:3689.
81. Schaefer IM, DeMatteo RP, Serrano C. The GIST of advances in treatment of advanced gastrointestinal stromal tumor. Am Soc Clin Oncol Educ Book 2022;42:1-15.
82. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731-9.
83. Rabban JT, Devine WP, Sangoi AR, et al. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma. Histopathology 2020;77:100-11.
84. Recine F, De Vita A, Fausti V, et al. Case report: adult NTRK-rearranged spindle cell neoplasm: early tumor shrinkage in a case with bone and visceral metastases treated with targeted therapy. Front Oncol 2021;11:740676.
Cite This Article
Export citation file: BibTeX | RIS
OAE Style
Gonzalez MR, Inchaustegui ML, Ruiz-Arellanos K, de Souza FF, Subhawong TK, Pretell-Mazzini J. Management of oligometastatic disease in soft tissue sarcomas. J Cancer Metastasis Treat 2023;9:12. http://dx.doi.org/10.20517/2394-4722.2022.132
AMA Style
Gonzalez MR, Inchaustegui ML, Ruiz-Arellanos K, de Souza FF, Subhawong TK, Pretell-Mazzini J. Management of oligometastatic disease in soft tissue sarcomas. Journal of Cancer Metastasis and Treatment. 2023; 9: 12. http://dx.doi.org/10.20517/2394-4722.2022.132
Chicago/Turabian Style
Gonzalez, Marcos R., Maria L. Inchaustegui, Kim Ruiz-Arellanos, Felipe F. de Souza, Ty K. Subhawong, Juan Pretell-Mazzini. 2023. "Management of oligometastatic disease in soft tissue sarcomas" Journal of Cancer Metastasis and Treatment. 9: 12. http://dx.doi.org/10.20517/2394-4722.2022.132
ACS Style
Gonzalez, MR.; Inchaustegui ML.; Ruiz-Arellanos K.; de Souza FF.; Subhawong TK.; Pretell-Mazzini J. Management of oligometastatic disease in soft tissue sarcomas. J. Cancer. Metastasis. Treat. 2023, 9, 12. http://dx.doi.org/10.20517/2394-4722.2022.132
About This Article
Copyright
Data & Comments
Data
0
Cite This Article 14 clicks
Like This Article 5
likes
Comments
Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at support@oaepublish.com.